Figure 3. The STING pathway is activated and the production of IL-4 and IFN-α is increased in CD4⁺ T cells from BLM-treated SKG mice in vivo. (A) Numbers of pSTING⁺ cells, pSTAT6⁺ cells, and pIRF3⁺ cells among CD4⁺ T cells from spleens of BLM-treated BALB/c mice (n=5) and SKG mice (n=4). (B) Spleen tissues of BLM-treated mice were stained with anti-CD4 (green), anti-pSTING (red), anti-pSTAT6 (red), and anti-pIRF3 (red) Abs. Scale bars=20 μm. (C) Numbers of IFN-α⁺ cells and IL-4⁺ IFN-α⁺ cells among CD4⁺ T cells from spleens of BLM-treated BALB/c mice (n=5) and SKG mice (n=4). (D) Spleen tissues of BLM-treated mice stained with anti-CD4 (green), anti-IL-4 (red), and anti-IFNα (blue) Abs. Scale bars=20 μm. (E) Splenocytes from spleen tissues of BLM-treated mice stained with anti-GM130 (green) and anti-STING (red) Abs. Scale bars=20 μm. (F) Immunohistochemistry of pSTING, pSTAT6, and pIRF3 in skin tissues in BLM-treated mice. Scale bars=100 μm. (G) Representative immunofluorescence images of CD4 (green), IL-4 (red), IFN-α (white), and DAPI (blue) in skin tissues from BLM-treated mice. Scale bars=20 μm. Values are means ± SEMs from three independent experiments.

GM130, Golgi matrix protein 130.

^*p<0.05, ^**p<0.01, and ^***p<0.001.